ArticlePLoS medicine2019
Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Association of Continuous Medicaid Eligibility With Postpartum Coverage and Opioid Use Disorder Treatment.American journal of preventive medicine · 2026Article
- Investigating heterogeneous effects of an expanded methadone access policy with opioid treatment program retention: a Rhode Island population-based retrospective cohort study.American journal of epidemiology · 2025Article
- Empowering Communities and Enhancing Public Safety: Stakeholders' Perspectives on Opioid Overdose Prevention Strategies in Boston.Community mental health journal · 2025Article
- A longitudinal observational study with ecological momentary assessment and deep learning to predict non-prescribed opioid use, treatment retention, and medication nonadherence among persons receiving medication treatment for opioid use disorder.Journal of substance use and addiction treatment · 2025Observational
- Assessing inequities in buprenorphine treatment across the care cascade.Drug and alcohol dependence · 2025Observational
- Reflections on the Collaborative Story Analysis Method to Understand Qualitative Perspectives of Indigenous Syringe Services Program Clients.SSM. Qualitative research in health · 2024Article
- Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.Drug and alcohol dependence · 2024Article
- Application of an opioid use disorder cascade of care in a large public health system.The American journal of drug and alcohol abuse · 2024Article
- Application of an Opioid Use Disorder Cascade of Care in a Large Public Health System.medRxiv : the preprint server for health sciences · 2023Article
- Community member perspectives on adapting the cascade of care for opioid use disorder for a tribal nation in the United States.Addiction (Abingdon, England) · 2023Article
- Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.Statistics in medicine · 2022Article
- Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.Lancet (London, England) · 2022Review
- Opioid use disorder Cascade of care framework design: A roadmap.Substance abuse · 2022Article
- Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.The International journal on drug policy · 2021Article
- Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota.Drug and alcohol dependence · 2021Article
- Improving transitions of care for patients initiated on buprenorphine for opioid use disorder from the emergency departments in King County, Washington.Journal of the American College of Emergency Physicians open · 2021Article
- Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.The American journal of drug and alcohol abuse · 2021Article
- "Rapid Start" Treatment to End the (Other) Epidemic: Walking the Tightrope Without a Net.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Care cascade for patients with opioid use disorder and serious injection related infections.Toxicology communications · 2021Article
- Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD. METHODS AND
findingsBetween June 2018 and May 2019, we engaged a diverse stakeholder group (including directors of statewide health and social service agencies) to develop a statewide, patient-centered cascade of care for OUD for Rhode Island, a small state in New England, a region highly impacted by the opioid crisis. Through an iterative process, we modified the cascade of care defined by Williams et al. for use in Rhode Island using key national survey data and statewide health claims datasets to create a cross-sectional summary of 5 stages in the cascade. Approximately 47,000 Rhode Islanders (5.2%) were estimated to be at risk for OUD (stage 0) in 2016. At the same time, 26,000 Rhode Islanders had a medical claim related to an OUD diagnosis, accounting for 55% of the population at risk (stage 1); 27% of the stage 0 population, 12,700 people, showed evidence of initiation of medication for OUD (MOUD, stage 2), and 18%, or 8,300 people, had evidence of retention on MOUD (stage 3). Imputation from a national survey estimated that 4,200 Rhode Islanders were in recovery from OUD as of 2016, representing 9% of the total population at risk. Limitations included use of self-report data to arrive at estimates of the number of individuals at risk for OUD and using a national estimate to identify the number of individuals in recovery due to a lack of available state data sources.
conclusionsOur findings indicate that cross-sectional summaries of the cascade of care for OUD can be used as a health policy tool to identify gaps in care, inform data-driven policy decisions, set benchmarks for quality, and improve health outcomes for persons with OUD. There exists a significant opportunity to increase engagement prior to the initiation of OUD treatment (i.e., identification of OUD symptoms via routine screening or acute presentation) and improve retention and remission from OUD symptoms through improved community-supported processes of recovery. To do this more precisely, states should work to systematically collect data to populate their own cascade of care as a health policy tool to enhance system-level interventions and maximize engagement in care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.